Brill Pharma is driving its international expansion by entering the Dutch market through an agreement with Tramedico for the distribution of Matrix Ocular® 3.
Brill Pharma continues to consolidate its international growth by adding the Netherlands to its global market network, as part of its expansion strategy in the field of ophthalmology.
In this context, last January the company reached an agreement with Tramedico for the distribution of Matrix Ocular® 3 in the Dutch market, marking a new milestone in its international development.
The arrival of Matrix Ocular® 3 in the Netherlands—and soon in other countries— reinforces Brill Pharma’s commitment to advancing ophthalmic care globally, bringing innovative solutions to healthcare professionals and patients in new markets.
This agreement joins other established collaborations in various countries, such as the distribution of Matrix Ocular® 3 in Morocco, Ocudox in Italy, and the Corneal Esthesiometer Brill in Asian markets like Singapore, China, and Japan, progressively expanding the company’s international presence.
Through innovative products such as Matrix Ocular® 3 and state-of-the-art diagnostic tools like the Corneal Esthesiometer Brill, the company works to improve people’s eye health, facilitating clinical practice and promoting the early detection and effective management of ocular surface diseases.